Okada Ken-ichi, Kawai Manabu, Tani Masaji, Hirono Seiko, Miyazawa Motoki, Shimizu Atsushi, Kitahata Yuji, Yamaue Hiroki
Second Department of Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8510, Japan.
J Hepatobiliary Pancreat Sci. 2014 Sep;21(9):648-53. doi: 10.1002/jhbp.109. Epub 2014 Apr 24.
The aim of the present study was to identify the predicting factors for unresectability and to clarify who should receive precise evaluations for distant metastasis and locally advanced unresectability in patients with pancreatic ductal adenocarcinoma (PDAC).
A total of 200 consecutive patients with PDAC who presented to the outpatient clinic between June 2009 and October 2012 were analyzed retrospectively. Clinical factors and the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, DUPAN-2 (pancreatic cancer-associated antigen) and CA 125 were analyzed.
Of the 200 patients who were investigated for PDAC, 60 (30%) were initially considered unresectable (15 patients with locally advanced tumors, 45 patients with distant metastases). Of the 136 (68%) patients who were surgically explored, 19 (9.5%) were detected to have minute metastases on laparotomy. A multivariate analysis revealed that tumor size (≥30 mm) and abnormalities in the levels of DUPAN-2 and CA 125 were independent predictors of unresectability (P = 0.002, 0.014, < 0.001, respectively). The patients with triple positive findings presented with the highest sensitivity (78.8%) for unresectability.
Patients with triple positive findings for a tumor size ≥30 mm, abnormalities in the levels of DUPAN-2 and CA 125 should receive precise evaluations for unresectability.
本研究旨在确定不可切除性的预测因素,并阐明在胰腺导管腺癌(PDAC)患者中谁应接受远处转移和局部晚期不可切除性的精确评估。
回顾性分析了2009年6月至2012年10月期间在门诊就诊的200例连续性PDAC患者。分析了临床因素以及癌胚抗原(CEA)、糖类抗原(CA)19-9、DUPAN-2(胰腺癌相关抗原)和CA 125的血清水平。
在200例接受PDAC检查的患者中,60例(30%)最初被认为不可切除(15例为局部晚期肿瘤,45例为远处转移)。在136例(68%)接受手术探查的患者中,19例(9.5%)在剖腹手术中被检测到有微小转移。多变量分析显示,肿瘤大小(≥30毫米)以及DUPAN-2和CA 125水平异常是不可切除性的独立预测因素(P分别为0.002、0.014、<0.001)。三项阳性结果的患者对不可切除性的敏感性最高(78.8%)。
肿瘤大小≥30毫米、DUPAN-2和CA 125水平异常三项阳性结果的患者应接受不可切除性的精确评估。